LOGIN  |  REGISTER
C4 Therapeutics
Cue Biopharma

Apollo Medical Releases Statement on the Mass Shooting in Monterey Park, Calif.

January 22, 2023 | Last Trade: US$ 36.83 0.00 0.00

ALHAMBRA, Calif., Jan. 22, 2023 /PRNewswire/ -- Apollo Medical Holdings, Inc. ("ApolloMed," and together with its subsidiaries and affiliated entities, the "Company") (NASDAQ: AMEH), a leading physician-centric, technology-powered healthcare company focused on enabling providers in the successful delivery of value-based care, today released a statement regarding the mass shooting incident that took place in Monterey Park, Calif., the evening of January 21, 2023. Current reports state that 10 people were killed, and at least 10 more were injured.

In response to the tragedy, Kenneth Sim, M.D., Chairman of the Board, and Co-Chief Executive Officers Thomas Lam, M.D. and Brandon Sim released the following statement:

"We are heartbroken and saddened to learn about the devastating acts of violence that occurred in our community last night, the eve of the Lunar New Year. This is the most important holiday of the year for many in our community, and what should have been a night of joyful celebration instead turned into one of senseless violence.

"We send our deepest condolences and prayers to the victims' families, friends, and all those who were affected by this tragic event. We mourn together.

"We commit to lend our full support to the families of the victims and the Monterey Park community as a whole, and are actively partnering with other community leaders to organize and deploy all available aid. Our clinics, urgent care/immediate access centers, and hospitalist program remain open during this time to serve the community with any medical needs they may have. This community, one we are proud to have been a part of for over 30 years, is extraordinarily strong and resilient, and by standing united, we can build towards a future where no one must experience such senseless tragedy."

Clinical Operations and Patient Care:

Our urgent care/immediate access centers and hospitalist program continue to be available throughout this period and are prepared to provide assistance to the communities we serve. Our local immediate access centers located at 120 W. Hellman Ave. in Monterey Park, Calif. and 101 Wheeler Ave. in Arcadia, Calif., will continue to operate during normal business hours 7 days a week to serve patients in this time of need.

We thank our teammates—our hospitalists, urgent care staff, frontline care providers, and more—who are stepping up during this difficult time to continue to provide care and support for our communities.

About Apollo Medical Holdings, Inc.

ApolloMed is a leading physician-centric, technology-powered, risk-bearing healthcare management company. Leveraging its proprietary end-to-end technology solutions, ApolloMed operates an integrated healthcare delivery platform that enables providers to successfully participate in value-based care arrangements, thus empowering them to deliver high quality care to patients in a cost-effective manner.

Headquartered in Alhambra, California, ApolloMed's subsidiaries and affiliates include management services organizations (MSOs), affiliated independent practice associations (IPAs), and entities participating in the Centers for Medicare & Medicaid Services Innovation Center (CMMI) innovation models. For more information, please visit www.apollomed.net.

FOR MORE INFORMATION, PLEASE CONTACT:
Investor Relations
(626) 943-6491
This email address is being protected from spambots. You need JavaScript enabled to view it.

Carolyne Sohn, The Equity Group
(408) 538-4577
This email address is being protected from spambots. You need JavaScript enabled to view it.

Surmodics

Stock Quote

Featured Stock

Amneal Pharmaceuticals

Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...

CLICK TO LEARN MORE

Featured Stock

Astria Therapeutics

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB